University of Maryland Medical Center

University of Maryland School of Medicine Begins Pediatric Trial of Moderna COVID-19 Vaccine

This Phase 2/3 Trial Will Test the Vaccine in Children Ages 6 Months to 11 Years

Newswise — BALTIMORE, April 29, 2021 – Researchers at the University of Maryland School of Medicine (UMSOM) on April 27 began enrolling children ages 6 months to 11 years old in a clinical trial of the Moderna mRNA-1273 COVID-19 vaccine, which has already received Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to prevent COVID-19 in people ages 18 years and older.

The study, called KidCOVE, will assess the safety and immunogenicity of mRNA-1273 in a pediatric population. The trial is being conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. UMSOM is one of multiple sites in the U.S. and Canada that will enroll approximately 6,750 children in two phases. Participants will receive two doses 28 days apart. The UMSOM site is expected to enroll 120 children

The vaccine trial is being conducted by researchers in UMSOM’s Center for Vaccine Development and Global Health (CVD) as part of their NIAID-funded Vaccine and Treatment Evaluation Unit (VTEU) work. It adds to the extensive COVID-19 vaccine research that has been underway on campus since spring 2020.

James Campbell, MD, MS, Professor of Pediatrics, is the principal investigator at the UMSOM site, which will enroll participants in Baltimore and Frederick, Maryland. Karen Kotloff, MD, Professor of Pediatrics, Associate Director for Clinical Research in CVD and principal investigator of the VTEU; Andrea Berry, MD, Assistant Professor of Pediatrics; Elizabeth Hammershaimb, MD, Postdoctoral Fellow, and other CVD experts also serve as investigators in this study.

“Children are not small adults. Medical research is very much needed to understand how best to keep them safe from a global pandemic that has killed so many,” Dr. Campbell said. “We hope KidCOVE will provide much awaited information to accomplish just that.”

Healthy boys and girls and children with stable chronic medical conditions will be considered for inclusion in KidCOVE. Study participation includes phone calls, telemedicine visits, and up to seven in-person visits to the study site.

“The KidCOVE study builds on the strong foundation of the CVD team through our ground-breaking work on the adult clinical trials of COVID-19 vaccines,” Kotloff said. “Collectively, we are at the forefront of the fight against the COVID-19 pandemic. The inclusion of children in these studies is long overdue, and we are pleased to be part of these efforts.”  

UMSOM’s participation in KidCOVE marks its first testing of a pediatric vaccine for COVID-19. CVD’s careful, meticulous work on the Pfizer, Moderna, and Novavax COVID-19 vaccine clinical studies, and its many decades of work with pediatric vaccines, led to this milestone.

“Our Center for Vaccine Development and Global Health continues to lead the way in conducting COVID-19 trials,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean at UMSOM. “This trial is critical in helping to protect children, who remain vulnerable until we develop and test safe, effective vaccines.”

The UMSOM VTEU is funded by federal contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the contract. The U.S. government has agreed to purchase supply of mRNA-1273 under U.S. Department of Defense contract no. W911QY-20-C-0100.

About the Moderna COVID-19 Vaccine

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19, co-developed by Moderna and the NIAID Vaccine Research Center. It received Emergency Use Authorization from the U.S. FDA in December 2020 for adults ages 18 years or older. 

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.

About the Center for Vaccine Development and Global Health

For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, malaria, and other infectious diseases. CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact. Currently, these diseases include typhoid, Shigella, E. coli diarrhea, malaria, and other vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Ebola and Zika. In addition, CVD’s work focuses on the ever-growing challenge of antimicrobial

 

 



Filters close

Showing results

110 of 5849
13-Jun-2021 12:05 PM EDT
COVID-19 Pandemic Drinking: Increases Among Women, Black Adults, and People with Children
Research Society on Alcoholism

Risky drinking has been a public health concern in the U.S. for decades, but the significant increase in retail alcohol sales following COVID-19 pandemic stay-at-home orders in particular raised red flags for alcohol researchers. New research has assessed changes in alcohol drinking patterns from before to after the enactment of stay-at-home orders. These results and others will be shared at the 44th annual scientific meeting of the Research Society on Alcoholism (RSA), which will be held virtually this year from the 19th - 23rd of June 2021 due to the COVID-19 pandemic.

13-Jun-2021 1:05 PM EDT
The Impact of the COVID-19 Pandemic on Alcohol Consumption Is Far From ‘One Size Fits All’
Research Society on Alcoholism

An ongoing analysis of the effects of the COVID-19 pandemic on alcohol and related outcomes shows that COVID-related stressors experienced by study participants – including work-, financial-, and family-related stressors – are having a varied impact on individuals with and without alcohol use disorders (AUDs). These results will be shared at the 44th annual scientific meeting of the Research Society on Alcoholism (RSA), which will be held virtually this year from the 19th - 23rd of June 2021 due to the COVID-19 pandemic.

Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
VIDEO
Released: 18-Jun-2021 2:10 PM EDT
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available
Newswise

Newswise is hosting a series of Expert Panels discussion on unique aspects of the COVID-19 pandemic. This tip sheet includes some notable quotes from the panelists.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Jun-2021 8:00 AM EDT Released to reporters: 18-Jun-2021 11:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Jun-2021 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded virtual-event-for-june-17-11am-edt-covid-19-vaccines-and-male-fertility
VIDEO
Released: 18-Jun-2021 8:55 AM EDT
VIDEO AND TRANSCRIPT AVAILABLE: Vaccines and Male Fertility Event for June 17, 2021
Newswise

This upcoming JAMA-published study examined whether the COVID-19 vaccine impacts male fertility.

access_time Embargo lifts in 2 days
Embargo will expire: 22-Jun-2021 11:00 AM EDT Released to reporters: 18-Jun-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 22-Jun-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Jun-2021 7:05 AM EDT
Teamwork saves lives: COVID-19 hospital network shares key findings to improve care
Michigan Medicine - University of Michigan

Data sharing among 40 Michigan hospitals about the care and outcomes for thousands of inpatients with COVID-19 has led to reduced variation and findings that could inform care anywhere, including approaches for preventing blood clots and reducing overuse of antibiotics, as well as a risk prediction tool.

Released: 18-Jun-2021 7:05 AM EDT
One-third of older Americans delayed health care over COVID concerns
Michigan Medicine - University of Michigan

Nearly one in three Americans between the ages of 50 and 80 put off an in-person appointment for medical care in 2020 because they were worried about exposure to the novel coronavirus, new national poll data show.

Released: 17-Jun-2021 4:15 PM EDT
UNC Researchers Lead Study of Diabetes Treatment of COVID-19 Patients
University of North Carolina School of Medicine

Diabetes is one of the comorbidities most strongly associated with severe COVID-19 in the US, and data from early in the pandemic suggested individuals with type 2 diabetes faced twice the risk of death from COVID-19 and a greater risk of requiring hospitalization and intensive care. A new study shows best treatment options.

Released: 17-Jun-2021 4:10 PM EDT
Vaccination, Previous Infection, Protect Against COVID-19 gamma/P.1 Variant in Animal Model
University of Wisconsin-Madison

In a new study using variant virus recovered from one of the original travelers, researchers in the U.S. and Japan have found that vaccination with an mRNA vaccine induces antibody responses that would protect humans from infection with the gamma/P.1 variant.


Showing results

110 of 5849

close
1.33194